Krystal Biotech, Inc.
KRYS · United States
Share price · KRYS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KRYS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+5.6%
- 2 Nov 2026-11.0%
- 30 Oct 2026+2.4%
Nothing announced by KRYS that day or the session before.
- 3 Aug 2026-8.4%
- 27 Jul 2026+5.0%
Nothing announced by KRYS that day or the session before.
- 14 Jul 2026-6.6%
Nothing announced by KRYS that day or the session before.
- 4 May 2026+7.9%
- 2 Mar 2026-6.1%
Nothing announced by KRYS that day or the session before.
- 19 Feb 2026-7.3%
Nothing announced by KRYS that day or the session before.
- 20 Jan 2026-3.6%
Nothing announced by KRYS that day or the session before.
Share of unusual movement by asset
For each asset, the share of KRYS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
Beremagene geperpavec(Vyjuvek) | Approved | COL7A1 (type VII collagen gene replacement)Gene therapy / editing | Dystrophic Epidermolysis Bullosa |
| Phase 1/2 | IL-12 / IL-2 (vector-encoded cytokines)Gene therapy / editing | Non-Small Cell Lung Cancer | |
| Phase 1 | CFTR (gene replacement)Gene therapy / editing | Cystic Fibrosis | |
| Phase 1 | SERPINA1 (alpha-1 antitrypsin; gene replacement)Gene therapy / editing | Alpha-1 Antitrypsin Deficiency |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
February 2027 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $127M | $15M | $463M+ $449M short-term inv. | —$91M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $119M | $15M | $428M+ $418M short-term inv. | —$75M operating cash flow | report ↗ |
| 2026-Q1 | $116M | $15M | $501M+ $322M short-term inv. | —$80M operating cash flow | report ↗ |
| 2025-Q3 | $98M | $15M | $393M+ $338M short-term inv. | —$40M operating cash flow | report ↗ |
| 2025-Q2 | $96M | $14M | $354M+ $328M short-term inv. | —$53M operating cash flow | report ↗ |
| 2025-Q1 | $88M | $14M | $309M+ $308M short-term inv. | —$31M operating cash flow | report ↗ |
| 2024-Q3 | $84M | $14M | $374M+ $214M short-term inv. | —$59M operating cash flow | report ↗ |
| 2024-Q2 | $70M | $16M | $346M+ $214M short-term inv. | —-$4.2M operating cash flow | report ↗ |
| 2024-Q1 | $45M | $11M | $359M+ $179M short-term inv. | —$16M operating cash flow | report ↗ |
| 2023-Q3 | $8.6M | $11M | $373M+ $189M short-term inv. | —-$21M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $12M | $276M+ $202M short-term inv. | $33M-$34M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $12M | $141M+ $210M short-term inv. | $45M-$26M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $12M | $186M+ $208M short-term inv. | $30M-$20M operating cash flow | report ↗ |
| 2022-Q2 | — | $11M | $219M+ $207M short-term inv. | $28M-$43M operating cash flow | report ↗ |
| 2022-Q1 | — | $9.3M | $269M+ $165M short-term inv. | $50M-$15M operating cash flow | report ↗ |
| 2021-Q3 | — | $6.1M | $287M+ $56M short-term inv. | $16M-$7.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $389M | $58M | $496M+ $331M short-term inv. | —$201M operating cash flow | report ↗ |
For fiscal year 2025, Krystal Biotech reported revenue of $389.13M, up 33.9% YoY, with R&D spend of $58.05M, up 8.4% YoY. The company held cash and equivalents of $496.3M and reported net income of $204.83M.
The filing highlights VYJUVEK’s approvals in the U.S., EU, and Japan for dystrophic epidermolysis bullosa, with 2025 launches in Germany, France, and Japan and a U.S. label update expanding eligibility from birth and increasing dosing flexibility. Pipeline activity includes clinical-stage candidates such as KB407 for cystic fibrosis and programs in ophthalmology and dermatology, and the FDA granted platform technology designation to the HSV-1 vector used in KB801 for neurotrophic keratitis. Cumulative VYJUVEK net product revenue since launch was $730.3M.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $291M | $54M | $345M+ $253M short-term inv. | —$123M operating cash flow | report ↗ |
| 2023-FY | $51M | $46M | $358M+ $174M short-term inv. | —-$89M operating cash flow | report ↗ |
| 2022-FY | $0 | $42M | $162M+ $217M short-term inv. | $35M-$101M operating cash flow | report ↗ |
| 2021-FY | $0 | $28M | $341M+ $97M short-term inv. | $17M-$48M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 142 sales ($105.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | ROSSI DINO A · director | Gift | 3,500 | — | — | Form 4 |
| 2026-09-14 | ROSSI DINO A · director | Award / grant (derivative) | 1,187 | — | — | Form 4 |
| 2026-09-14 | Gangolli Julian S · director | Award / grant (derivative) | 1,187 | — | — | Form 4 |
| 2026-09-14 | JANNEY DANIEL · director | Award / grant (derivative) | 1,187 | — | — | Form 4 |
| 2026-09-14 | Mason Christopher · director | Award / grant (derivative) | 1,187 | — | — | Form 4 |
| 2026-09-14 | Mazzacco Catherine · director | Award / grant (derivative) | 1,187 | — | — | Form 4 |
| 2026-09-14 | Sutherland Everett Rand · director | Award / grant (derivative) | 1,187 | — | — | Form 4 |
| 2026-09-14 | ROSSI DINO A · director | Award / grant (derivative) | 471 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 365 reporting institutions held 28.4M shares ($7.1B).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 4,373,987 | $1.1B |
| 2 | BlackRock, Inc. | 3,940,456 | $1.0B |
| 3 | Avoro Capital Advisors LLC | 2,888,888 | $746.3M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,456,727 | $376.3M |
| 5 | STATE STREET CORP | 1,314,434 | $339.5M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,165,324 | $301.0M |
| 7 | Soleus Capital Management, L.P. | 1,153,087 | $297.9M |
| 8 | Capital World Investors | 824,720 | $213.0M |
| 9 | Redmile Group, LLC | 673,505 | $174.0M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 643,975 | $166.4M |
| 11 | Hood River Capital Management LLC | 619,586 | $160.1M |
| 12 | Bellevue Group AG | 481,785 | $124.5M |
| 13 | Frazier Life Sciences Management, L.P. | 481,307 | $124.3M |
| 14 | DIMENSIONAL FUND ADVISORS LP | 468,990 | $121.1M |
| 15 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 407,178 | $105.2M |